Compounds > 1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol
Page last updated: 2024-09-03

1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol and tirapazamine

1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol has been researched along with tirapazamine in 1 studies

Compound Research Comparison

Studies
(1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol)		Trials
(1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol)		Recent Studies (post-2010)
(1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol)		Studies
(tirapazamine)		Trials
(tirapazamine)		Recent Studies (post-2010) (tirapazamine)
190048444133

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hall, EJ; He, ZY; Hei, TK; Piao, CQ1

Other Studies

1 other study(ies) available for 1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol and tirapazamine

ArticleYear
Mechanism of oncogenicity for bioreductive drugs.
    International journal of radiation oncology, biology, physics, 1992, Volume: 22, Issue:4

    Topics: Animals; Antineoplastic Agents; Aziridines; Cell Hypoxia; Cell Line; Cell Transformation, Neoplastic; Mice; Misonidazole; Neoplasms, Second Primary; Nitrofurans; Prodrugs; Radiation-Sensitizing Agents; Risk; Tirapazamine; Triazines

1992